KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Revenue (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Revenue for 15 consecutive years, with $211.6 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 21.48% to $211.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $719.0 million through Dec 2025, up 8.63% year-over-year, with the annual reading at $719.0 million for FY2025, 8.63% up from the prior year.
  • Revenue for Q4 2025 was $211.6 million at Supernus Pharmaceuticals, up from $192.1 million in the prior quarter.
  • The five-year high for Revenue was $211.6 million in Q4 2025, with the low at $130.9 million in Q1 2021.
  • Average Revenue over 5 years is $161.8 million, with a median of $161.7 million recorded in 2021.
  • The sharpest move saw Revenue skyrocketed 37.86% in 2021, then fell 20.28% in 2023.
  • Over 5 years, Revenue stood at $159.0 million in 2021, then rose by 5.2% to $167.3 million in 2022, then dropped by 1.8% to $164.3 million in 2023, then rose by 5.99% to $174.2 million in 2024, then increased by 21.48% to $211.6 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $211.6 million, $192.1 million, and $165.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.